Report cover image

Adult-onset growth hormone deficiency - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679185

Description

Adult-onset growth hormone deficiency - Pipeline Insight, 2024



DelveInsight’s, “Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adult Growth Hormone Deficiency (AGHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Adult Growth Hormone Deficiency (AGHD) Understanding

Adult Growth Hormone Deficiency (AGHD): Overview

Adult Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Most cases of Adult Growth Hormone Deficiency (AGHD) result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult Growth Hormone Deficiency (AGHD) is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.

""Adult Growth Hormone Deficiency (AGHD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adult Growth Hormone Deficiency (AGHD) pipeline landscape is provided which includes the disease overview and Adult Growth Hormone Deficiency (AGHD) treatment guidelines. The assessment part of the report embraces, in depth Adult Growth Hormone Deficiency (AGHD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adult Growth Hormone Deficiency (AGHD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Adult Growth Hormone Deficiency (AGHD) R&D. The therapies under development are focused on novel approaches to treat/improve Adult Growth Hormone Deficiency (AGHD).
Adult Growth Hormone Deficiency (AGHD) Emerging Drugs Chapters

This segment of the Adult Growth Hormone Deficiency (AGHD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adult Growth Hormone Deficiency (AGHD) Emerging Drugs
  • Sogroya (somapacitan-beco): Novo Nordisk
Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco. The drug is registered in USA for the treatment of growth hormone deficiency in adults.
  • TransCon hGH: Ascendis Pharma
TransCon hGH is an investigational prodrug of somatropin (human growth hormone) in phase 3 development as a once-weekly therapy for children and adults with GHD. TransCon hGH has orphan designation for GHD in both the U.S. and Europe.

Further product details are provided in the report……..

Adult Growth Hormone Deficiency (AGHD): Therapeutic Assessment

This segment of the report provides insights about the different Adult Growth Hormone Deficiency (AGHD) drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Adult Growth Hormone Deficiency (AGHD)
There are approx. 3+ key companies which are developing the therapies for Adult Growth Hormone Deficiency (AGHD). The companies which have their Adult Growth Hormone Deficiency (AGHD) drug candidates in the mid to advanced stage, i.e. phase III include, Ascendis Pharma and others.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Adult Growth Hormone Deficiency (AGHD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adult Growth Hormone Deficiency (AGHD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adult Growth Hormone Deficiency (AGHD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adult Growth Hormone Deficiency (AGHD) drugs.

Adult Growth Hormone Deficiency (AGHD) Report Insights
  • Adult Growth Hormone Deficiency (AGHD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Adult Growth Hormone Deficiency (AGHD) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Adult Growth Hormone Deficiency (AGHD) drugs?
  • How many Adult Growth Hormone Deficiency (AGHD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adult Growth Hormone Deficiency (AGHD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adult Growth Hormone Deficiency (AGHD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Adult Growth Hormone Deficiency (AGHD) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Novo Nordisk
  • Ascendis Pharma
Key Products
  • Sogroya
  • TransCon hGH

Table of Contents

40 Pages
Introduction
Executive Summary
Adult Growth Hormone Deficiency (AGHD): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Adult Growth Hormone Deficiency (AGHD) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adult Growth Hormone Deficiency (AGHD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adult Growth Hormone Deficiency (AGHD) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late -stage Products (Phase III)
Comparative Analysis
TransCon hGH: Ascendis Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Adult Growth Hormone Deficiency (AGHD) Key Companies
Adult Growth Hormone Deficiency (AGHD) Key Products
Adult Growth Hormone Deficiency (AGHD)- Unmet Needs
Adult Growth Hormone Deficiency (AGHD)- Market Drivers and Barriers
Adult Growth Hormone Deficiency (AGHD)- Future Perspectives and Conclusion
Adult Growth Hormone Deficiency (AGHD) Analyst Views
Adult Growth Hormone Deficiency (AGHD) Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us